Engage Bio logo
YC W22

Engage Bio

Potent, durable, and redosable non-viral genetic medicines

engagebio.com

About

Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine. In 2026 Engage was acquired by Eli Lilly.

Founder

Family Office Investors

1 deal tracked

Altss has tracked family office activity in Engage Bio. Investors shown are from our private markets database.

  • Will Olsen (Angel)
Request access to full investor list

Industry & Focus

HealthcareTherapeuticsSynthetic BiologyBiotechDrug discovery